Latest Period
Q2 2026
Security Snapshot
Avalyn Pharma Inc. - Voting Common Stock, par value $0.001 per share (AVLN) Institutional Ownership
CUSIP: 05348Y105
13F Institutional Holders and Ownership History for Q2 2026
Institutions Reporting
92
Shares (Excl. Options)
44,014,445
Price
$32.92
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Voting Common Stock, par value $0.001 per share
- Symbol
- AVLN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 44,014,445
- Total 13F value
- $1,448,925,682
- Portfolio coverage rank
- 0.01%
- Share change
- +44,002,718
- Value change
- +$1,448,559,385
- Number of holders
- 92
- Shares outstanding
- 44,128,284
- SEC-reported price per share
- $28.10
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AVLN - Avalyn Pharma Inc. - Voting Common Stock, par value $0.001 per share is tracked under CUSIP 05348Y105.
- 92 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q2 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 92 institutions filings for Q2 2026.
Security key
05348Y105
Latest holder period
Q2 2026
13F holders
92
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
AVLN full holder history
Avalyn Pharma Inc. SEC filings
Avalyn Pharma Inc. company facts
Avalyn Pharma Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 05348Y105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AVLN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | $162,453,611 | 5,835,259 | FMR LLC | 30 Jun 2026 | |||
| Novo Holdings A/S | 8.8% | $108,110,766 | 3,883,289 | Novo Holdings A/S | 30 Jun 2026 | |||
| Norwest Venture Partners XV, LP | 5.1% | $63,152,367 | 2,268,404 | Norwest Venture Partners XV, LP | 30 Jun 2026 |
As of 30 Jun 2026, 92 institutional investors reported holding 44,014,445 shares of Avalyn Pharma Inc. - Voting Common Stock, par value $0.001 per share (AVLN). This represents 100% of the company’s total 44,128,284 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
91%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 13% | 5,835,259 | 0.01% | $192,096,726 | |
| NOVO HOLDINGS A/S | 8.8% | 3,883,289 | 7.5% | $127,837,874 | |
| SR One Capital Management, LP | 7.5% | 3,308,649 | 10% | $108,920,725 | |
| PERCEPTIVE ADVISORS LLC | 6.1% | 2,675,296 | 1.4% | $88,070,744 | |
| MONTANOVA CAPITAL, LLC | 5.7% | 2,503,109 | 1.7% | $82,402,348 | |
| NVP ASSOCIATES, LLC | 5.1% | 2,268,404 | 23% | $74,675,860 | |
| WELLINGTON MANAGEMENT GROUP LLP | 5% | 2,201,986 | 0.01% | $72,489,379 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.9% | 1,735,231 | 0.01% | $57,124,000 | |
| Catalio Capital Management, LP | 3.8% | 1,675,830 | 10% | $55,168,324 | |
| T. Rowe Price Investment Management, Inc. | 3.6% | 1,602,745 | 0.03% | $52,763,000 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.1% | 1,375,486 | 0.61% | $45,280,999 | |
| Bellevue Group AG | 3.1% | 1,350,000 | 0.94% | $44,442,000 | |
| BlackRock, Inc. | 2.2% | 977,264 | 0% | $32,171,531 | |
| Pivotal bioVenture Partners Investment Advisor LLC | 2.2% | 966,792 | 10% | $31,826,793 | |
| CITADEL ADVISORS LLC | 2.2% | 959,098 | 0.02% | $31,573,506 | |
| ANDERA PARTNERS | 2.1% | 929,824 | 15% | $30,609,806 | |
| JENNISON ASSOCIATES LLC | 1.8% | 812,749 | 0.02% | $26,755,697 | |
| BRAIDWELL LP | 1.8% | 801,395 | 0.98% | $26,381,923 | |
| TPG GP A, LLC | 1.8% | 773,069 | 0.51% | $25,449,431 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 739,770 | 0% | $24,353,228 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.7% | 731,000 | 0.25% | $24,064,520 | |
| Rock Springs Capital Management LP | 1.5% | 662,918 | 1.1% | $21,823,261 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.98% | 434,650 | 0% | $14,312,229 | |
| Soleus Capital Management, L.P. | 0.95% | 419,000 | 0.48% | $13,793,480 | |
| INFINITUM ASSET MANAGEMENT, LLC | 0.93% | 411,378 | 1.4% | $13,542,564 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q2 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 44,014,445 | $1,448,925,682 | +$1,448,559,385 | $32.92 | 92 |